Literature DB >> 8738316

Considerable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type under treatment with clozapine.

T Steinert1, P O Schmidt-Michel, W P Kaschka.   

Abstract

We report on a 27-year-old woman with previously therapy-resistant obsessive-compulsive disorder and emotionally unstable personality disorder, borderline type, which improved considerably on treatment with clozapine. Previous treatment attempts with paroxetine, clomipramine and various classic and atypical neuroleptics, as well as extensive psychotherapeutic treatment, had proved ineffective.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738316     DOI: 10.1055/s-2007-979555

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  6 in total

1.  Treatment of severe borderline personality disorder with clozapine.

Authors:  Adarsh Kumar Vohra
Journal:  Indian J Psychiatry       Date:  2010-07       Impact factor: 1.759

2.  Clozapine for Treatment-Refractory Aggressive Behavior.

Authors:  Teodorescu Andreea; Ifteni Petru; Ana Aliana Miron; Petric Paula-Simina; Dima Lorena
Journal:  Psychiatr Q       Date:  2020-09-12

Review 3.  Medications in the treatment of borderline personality disorder 2006.

Authors:  Deanna Mercer
Journal:  Curr Psychiatry Rep       Date:  2007-02       Impact factor: 8.081

Review 4.  Drug treatment of obsessive-compulsive disorder.

Authors:  Michael Kellner
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

Review 5.  Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders.

Authors:  Dongmi Kim; Nicole L Ryba; Julie Kalabalik; Ligia Westrich
Journal:  Drugs R D       Date:  2018-09

6.  Use of Clozapine for Borderline Personality Disorder: A Case Report.

Authors:  Badii Amamou; Walid Bel Hadj Salah; Ahmed Mhalla; Nejla Benzarti; Hend Elloumi; Ferid Zaafrane; Lotfi Gaha
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-05-31       Impact factor: 2.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.